PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy

Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential of CA-170, which has advanced to human clinical tr...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Pottayil G. Sasikumar, Naremaddepalli S. Sudarshan, Srinivas Adurthi, Raghuveer K. Ramachandra, Dodderi S. Samiulla, Anirudha Lakshminarasimhan, Anuradha Ramanathan, Talapaneni Chandrasekhar, Amit A. Dhudashiya, Sumalatha R. Talapati, Nagesh Gowda, Sreenivasulareddy Palakolanu, Jiju Mani, Bandi Srinivasrao, David Joseph, Nigam Kumar, Rashmi Nair, Hanudatta S. Atreya, Nagaraj Gowda, Murali Ramachandra
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Biology (General)
QH301-705.5
Accès en ligne:https://doaj.org/article/0dc6fdd12b8e4be4a3c38267bc1cd96a
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
Description
Résumé:Sasikumar et al. describe the identification and characterization of CA-170, a small molecule inhibitor of PD-L1 and VISTA. They find that CA-170 activates T cells and exhibits anti-tumor efficacy in mouse models. This study highlights the potential of CA-170, which has advanced to human clinical trials, as an anti-cancer drug.

Documents similaires